When to have a sore joint looked at

When to seek care sooner

When a single joint feels hot and looks swollen, prompt care matters even more if fever is present. Please call your doctor or an urgent-care office that day.

After a fall, get prompt help if the joint looks out of shape. Trouble standing on the leg also needs care that day.

Call the office if the red area grows or the ache climbs quickly after a procedure. Don’t wait for the next planned visit to report those changes.

Sudden weakness after an injury needs prompt care. New numbness with loss of bladder or bowel control means you’ll need the emergency room rather than a regular appointment.

Soreness that grows slowly is less urgent, but it still deserves an exam. Please book when sleep, errands, or steady walking become difficult.

What to bring to the visit

Bring a list of medicines and supplements, along with old reports and notes about the ache. Include when soreness starts, what eases it, and which activity has become difficult.

The provider may ask about sleep, walking, past care, and other health concerns. You’re welcome to bring a family member who can listen and take notes.

An exam may be enough, or the provider may discuss an X-ray. Please ask what the X-ray would tell you before agreeing.

For now, avoid motions that cause a sharp catch and keep comfortable movement in your day. You needn’t stop every activity that still feels safe.

At QC Kinetix, Chandler consultations include an exam and a talk about joint preservation, meaning non-surgical regenerative care made with blood drawn from your arm or marrow from the pelvis.

Sources

1. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

2. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

3. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

4. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-rich and leukocyte-poor PRP significantly superior to placebo and to hyaluronic acid for function at 6-12 months (MD vs placebo -13.20 and -10.54 respectively). LP-PRP ranked highest (P-score 0.96) but the DIRECT comparison between the two formulations showed no statistically significant difference, and the authors concluded there is insufficient evidence to recommend one PRP formulation over the other.

   Xu B, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026. DOI: 10.1186/s13018-026-06689-4.

5. In a 2-year double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, 40 mg intra-articular triamcinolone every 12 weeks produced significantly greater cartilage volume loss than saline (index compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with no significant difference in knee pain.

   McAlindon TE, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.